+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of opevesostat combined with daily corticosteroids compared to alternative hormonal agents abiraterone acetate or enzalutamide in adults with metastatic castration-resistant prostate cancer mCRPC who have previously received one next-generation hormonal agent. This Phase 3 randomized study aims to determine if opevesostat improves overall survival in participants with or without androgen receptor ligand binding domain mutations. Participants in the experimental group will take opevesostat 5 mg orally twice daily along with dexamethasone 1.5 mg and fludrocortisone acetate 0.1 mg once daily continuously until their disease progresses. Hydrocortisone is available as a rescue medication. The comparison group will receive abiraterone 1000 mg once daily plus prednisone 5 mg twice daily or enzalutamide 160 mg once daily until disease progression. Treatments are oral medications administered daily. During the study, participants will be monitored for overall survival up to about 82 months, along with other outcomes such as progression-free survival, time to new treatments, response rates, pain progression, and quality of life assessments. Safety will be tracked by recording adverse events and treatment discontinuations. The total study duration may last up to nearly seven years, including follow-up assessments to evaluate long-term effects and benefits.

Age: 18Years +All GendersPhase 3
330 locations
O

Actively Recruiting

Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.

Age: 50Years +All GendersPhase 3
566 locations
R

Actively Recruiting

Researchers are evaluating the similarity in effectiveness between ABP 938 8 mg and Aflibercept US 8 mg in people with neovascular age-related macular degeneration nAMD. The study aims to compare changes in best corrected visual acuity BCVA to understand how these treatments perform in improving vision for participants with this eye condition. Participants will be randomly assigned to receive intravitreal injections of either ABP 938 8 mg or Aflibercept 8 mg at the start of the study, Week 4, and Week 8. After these initial doses, participants will be regularly assessed starting at Week 16 to adjust injection schedules based on disease activity. The injections may then continue at intervals ranging from every 4 to 16 weeks up until the end of the study. Throughout the trial, participants will attend scheduled visits where vision tests like BCVA and imaging scans such as spectral-domain optical coherence tomography SD-OCT and fluorescein angiography FA will be performed. Researchers will monitor changes in vision, retinal fluid presence, lesion size, and safety outcomes including adverse events and immune responses. The study includes ongoing assessments of drug levels in blood samples, with participation lasting through multiple weeks with continuous monitoring.

Age: 50Years +All GendersPhase 3
81 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of ponsegromab combined with systemic chemotherapy compared to chemotherapy plus placebo for adults with metastatic pancreatic ductal adenocarcinoma mPDAC who have cachexia, a condition causing significant weight loss and fatigue. This Phase 2b3, randomized, double-blind study involves adult participants who have completed initial chemotherapy cycles and aims to improve treatment outcomes for this challenging condition. Participants will receive either one of two doses of ponsegromab or a placebo alongside first-line chemotherapy regimens consisting of nab-paclitaxel plus gemcitabine or FOLFIRINOX. The study intervention is given as a subcutaneous injection every four weeks. After an initial Phase 2b period where doses are evaluated, the study continues into Phase 3 with the selected ponsegromab dose or placebo. Participants may also join an optional open-label extension to receive ponsegromab for up to 12 months after the double-blind phase ends. During the study, participants will have tumor assessments approximately every 6 to 8 weeks by independent radiologists. The research team will monitor body weight changes, physical activity, quality of life measures, safety events, and survival outcomes over the course of the trial, which may last up to several years. Caregiver quality of life is also evaluated in an optional sub-study. Participants health and treatment effects will be closely followed until the studys completion in 2029.

Age: 18Years +All GendersPhase 2Phase 3
230 locations
P

Actively Recruiting

Researchers are evaluating the investigational drug PF-06821497 mevrometostat combined with enzalutamide compared to enzalutamide alone in men with metastatic castration-resistant prostate cancer mCRPC who have not previously received certain systemic treatments. This global, multicenter, randomized Phase 3 study focuses on participants who have mCRPC but have only received androgen deprivation therapy or first-generation anti-androgen agents, excluding prior treatment with androgen receptor signaling inhibitors such as enzalutamide or abiraterone. Participants are randomly assigned to one of two groups one receiving PF-06821497 twice daily plus enzalutamide once daily, and the other receiving a placebo twice daily plus enzalutamide once daily. The study includes several phases screening, randomization, treatment, safety follow-up, and long-term follow-up. Treatment is continuous oral dosing during the treatment phase. Throughout the study, participants will undergo regular assessments including scans, laboratory tests, and patient-reported questionnaires to measure outcomes such as radiographic progression-free survival, overall survival, pain progression, prostate specific antigen levels, and quality of life. Safety is monitored continuously, and follow-up can last up to approximately five years after randomization to evaluate long-term effects and treatment impact.

Age: 18Years +MALEPhase 3
231 locations
E

Actively Recruiting

Researchers are evaluating the medicine BI 1815368 in adults aged 18 and older who have a specific eye condition called centre-involved diabetic macular edema CI-DME, a type of diabetic macular edema. The purpose is to determine if BI 1815368 helps improve vision and to identify the best dose. This randomized, double-masked, placebo-controlled Phase 2 trial is sponsored by Boehringer Ingelheim. The study has two parts. In the first part, participants are randomly assigned to take either BI 1815368 tablets or placebo tablets that look identical but contain no medicine. In the second part, participants are randomly assigned to one of four groups three groups receive different daily doses of BI 1815368, and one group receives placebo. All participants take tablets twice daily for about 11 months. Participants stay in the study for about one year, visiting the study site at least 16 times. Those taking metformin have three extra visits. At each visit, doctors check vision, record any health issues, and take detailed pictures of the eye using advanced imaging. Researchers compare vision changes over time between groups to assess the medicines effect. Safety and tolerability are also monitored throughout the study.

Age: 18Years +All GendersPhase 2
97 locations
I

Actively Recruiting

Researchers are evaluating the efficacy and safety of lutetium 177Lu vipivotide tetraxetan AAA617 in adult male participants with oligometastatic prostate cancer OMPC that is progressing after definitive treatment to the primary tumor. The study aims to delay progression to fatal metastatic disease and preserve quality of life by postponing androgen deprivation therapy ADT. This is a Phase III, open-label, randomized trial involving participants with PSMA-positive OMPC. Participants will undergo baseline disease assessments including PETCT scans using gallium 68Ga gozetotide or piflufolastat 18F, along with CTMRI and bone scans. All will receive Stereotactic Body Radiation Therapy SBRT to metastatic lesions over about three weeks. Those in the investigational group will then receive up to four cycles of AAA617 infusions every six weeks. Participants in the control group will be observed after SBRT without additional treatment. Visits occur weekly during cycles and every 16 weeks thereafter until disease progression. During the study, participants will be monitored through regular imaging and clinical assessments to track disease progression and side effects. Outcome measures include metastasis-free survival, time to hormonal therapy, PSA progression, quality of life questionnaires, and safety events, with follow-up lasting approximately 7.5 years. This comprehensive monitoring seeks to understand the treatments impact on delaying progression and maintaining patient well-being over time.

Age: 18Years - 100YearsMALEPhase 3
144 locations
C

Actively Recruiting

Pelvic organ prolapse POP, especially defects in the anterior compartment, significantly affects the quality of life in women. This trial focuses on comparing two surgical methods to repair cystocele, a common type of POP caused mainly by paravaginal defects in vaginal support. The study aims to evaluate the safety and effectiveness of a new minimally invasive surgery called transobturator cystocele repair TOCR against the standard anterior colporrhaphy AR to improve cystocele repair outcomes over one year. Participants will receive either the novel TOCR procedure or the standard AR surgery. TOCR involves a transvaginal approach using continuous non-locking stitches through the obturator membrane and muscle with non-absorbable sutures, followed by closure of the vaginal skin. The AR technique uses a midline vaginal incision to dissect and repair the pubocervical fascia with interrupted sutures and trims excess vaginal tissue. Both groups receive indometacin rectal suppositories for early postoperative pain management. Women in the trial will undergo assessments before and after surgery, including anatomical evaluations of prolapse repair success at 1 and 2 years, complication monitoring, pain assessment 14 days post-surgery, and questionnaires on subjective improvement and quality of life related to urinary and pelvic symptoms. The study includes follow-up visits to measure patient satisfaction and monitor new urinary symptoms. The total follow-up period extends up to two years to observe long-term outcomes and safety.

Age: 50Years +FEMALEPhase Not Applicable
8 locations
R

Actively Recruiting

Researchers are evaluating whether combining the investigational drug mevrometostat PF-06821497 with enzalutamide works better than enzalutamide alone in men with metastatic castration-sensitive prostate cancer mCSPC who have not received androgen receptor pathway inhibitors or chemotherapy for mCSPC. This Phase 3, global, multicenter, randomized, double-blind, placebo-controlled study focuses on participants with prior limited androgen-deprivation therapy and no disease progression or rising PSA before treatment starts. Participants are randomly assigned to one of two groups one receives mevrometostat 875 mg twice daily plus enzalutamide 160 mg once daily, and the other receives a placebo plus enzalutamide at the same dose. The study includes a screening phase, treatment phase, safety follow-up, and long-term follow-up. Treatment is oral and taken continuously during the trial. During the study, participants undergo various assessments including imaging scans to track disease progression, laboratory tests, and patient-reported questionnaires on pain, quality of life, and fatigue. Researchers will monitor radiographic progression-free survival for up to about 4 years and overall survival for up to about 9 years. Safety and pharmacokinetics of mevrometostat combined with enzalutamide are also evaluated. The total duration includes screening, treatment, safety monitoring, and extended follow-up phases.

Age: 18Years +MALEPhase 3
319 locations

1-10 of 11

1